Vaginal Ring comprising DHEA or DHEA sulfate Agent and optionally a Modulator of the release of the active principle, useful to increase Primary ovarian reserve in Women and alleviate symptoms associated with Menopause

摘要

Vaginal Ring sustained Release comprising as active ingredient dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (dhea-s) or a pharmaceutically acceptable Salt thereof and, Optionally, a modulating Agent release of the active substance, where the amount of ing Active rediente lies between 1% to 32% by weightIn relation to the total weight of the formulation and the modulating Agent is selected from: polyvinylpyrrolidone k-30, lactose, microcrystalline Cellulose and Sodium lauryl sulfate.The Vaginal Ring of the present Invention is useful to improve the ovarian reserve in Women, to be used as a Medicine in Assisted Reproduction Programs and to relieve Symptoms related to menopause, such as symptoms of vulvovaginal atrophy and Sexual Dysfunction in m Post menopausal Women.